Ocular Inflammation
📧 Sign up to get email alerts when something new happens for Ocular Inflammation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Dextenza in the Post-op Management of Vitreoretinal Surgeries [Phase 4]
Phase 4 clinical trial update evaluating Dextenza for post-operative management of vitreoretinal surgeries, focusing on ocular inflammation …
-
FDA approval · 2025-12-10FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' original ANDA for Loteprednol etabonate and tobramycin ophthalmic suspension, a combination eye drop f…
-
FDA approval · 2025-09-23FDA Approved: FLAREX — Supplemental Application (Eyevance Pharmaceuticals)
The FDA granted a supplemental approval for FLAREX (fluorometholone acetate) by Eyevance Pharmaceuticals. The notice indicates FDA approval …
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses) [Phase 3]
A Phase 3 clinical trial evaluating a topical treatment for inflammatory secretions of the conjunctiva in patients with ocular prostheses. T…
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]
Phase 3 study evaluating the efficacy and safety of OCS-01 eyedrops versus vehicle for ocular inflammation and pain after cataract surgery h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: Bromfenac Versus Dexamethasone After Cataract Surgery [Phase 4]
The completed Phase 4 study compares bromfenac with dexamethasone for inflammation after cataract surgery.
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery [Phase 2]
Phase 2 trial of VVN461 Ophthalmic Solution for post-operative ocular inflammation after cataract surgery has completed and results have bee…
-
FDA approval · 2025-05-20FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved the original application for Loteprednol etabonate ophthalmic drops from Amneal Pharmaceuticals NY LLC, providing a generic…
-
FDA approval · 2025-03-20FDA Approved: DIFLUPREDNATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approves Mylan's original generic application for difluprednate ophthalmic 0.05% (DIFLUPREDNATE) for reduction of ocular inflammation an…
-
FDA approval · 2025-01-28FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (ARMAS PHARMACEUTICALS INC.)
FDA approves a supplemental application for Loteprednol Etabonate from Armas Pharmaceuticals Inc. under ANDA 212080, finalizing the status o…
-
FDA approval · 2024-12-13FDA Approved: DIFLUPREDNATE — Original Application (Caplin Steriles Limited)
The FDA approved Caplin Steriles Limited's original application for difluprednate, a generic ophthalmic corticosteroid, for treating ocular …
-
FDA approval · 2024-12-13FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's Loteprednol etabonate ophthalmic suspension as an original generic application (ANDA).
-
CLINICAL_TRIALS other · 2024-12-10Clinical Trial Update: Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery [Phase 3]
A Phase 3 trial evaluating OCS-01 eye drops for postoperative inflammation after cataract surgery was terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy of an Oral Supplement in Supporting Vision and Eye Health [NA]
This document reports the completion of a clinical trial evaluating an oral supplement intended to support vision and eye health.
-
FDA approval · 2024-07-10FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Padagis US LLC)
FDA approves Padagis US LLC Loteprednol etabonate ophthalmic suspension under an original ANDA application.
-
FDA approval · 2024-04-24FDA Approved: LOTEPREDNOL ETABONATE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original application for Loteprednol etabonate, a generic ophthalmic corticosteroid for inflammatory eye…
-
CLINICAL_TRIALS trial_result · 2023-07-05Clinical Trial Update: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery [Phase 3]
Phase 3 trial update on APP13007 for ocular inflammation and pain after cataract surgery; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery [Phase 2]
Phase 2 trial of RTA 408 ophthalmic suspension for ocular inflammation and pain following ocular surgery has completed, with results posted …
-
FDA approval · 2023-04-12FDA Approved: LOTEPREDNOL ETABONATE — Original Application (ARMAS PHARMACEUTICALS INC.)
FDA approved Loteprednol etabonate ophthalmic suspension from Armas Pharmaceuticals Inc. under an Original Application for use in ocular inf…
-
FDA approval · 2023-03-09FDA Approved: BROMSITE 0.075% — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for BromSite 0.075% (bromfenac) from Sun Pharmaceutical Industries, likely updating labeling or …
-
CLINICAL_TRIALS trial_result · 2022-03-07Clinical Trial Update: Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification [Phase 2]
A Phase 2 trial update reports efficacy and safety of Saturno IIB association for controlling ocular inflammation after cataract surgery.
-
FDA approval · 2021-02-10FDA Approved: LOTEPREDNOL ETABONATE — Original Application (ARMAS PHARMACEUTICALS INC.)
FDA approved the original application for Loteprednol etabonate ophthalmic suspension from Armas Pharmaceuticals, establishing the generic c…
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation [Phase 3]
Phase 3 trial assessing KPI-121 for safety and efficacy in postsurgical ocular inflammation/infection completed with posted results.
-
FDA approval · 2020-10-26FDA Approved: EYSUVIS — Original Application (ALCON LABORATORIES, INC.)
FDA approved EYSUVIS (loteprednol etabonate) ophthalmic suspension from Alcon for short-term treatment of ocular inflammation after ocular s…
-
CLINICAL_TRIALS trial_result · 2020-09-03Clinical Trial Update: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery [Phase 3]
Phase 3 trial update for mapracorat ophthalmic suspension 3% aimed at treating ocular inflammation and pain after cataract surgery; study co…